| Bioactivity | Evenamide (NW-3509) is an orally available voltage-gated sodium channel (VGSC) blocker (Ki=0.4 µM) for the research of schizophrenia. Evenamide shows efficacy in a broad spectrum of rodent models of psychosis, mania, depression, and aggressiveness[1][2]. | ||||||||||||
| Target | Sodium channel | ||||||||||||
| Invitro | Evenamide selectively blocks voltage-gated sodium channels (VGSCs) in a voltage-and use-dependent manner (Ki=0.4 µM) and modulates sustained repetitive firing without inducing impairment of the normal neuronal excitability. Evenamide does not bind, inhibit or interact with over 130 receptors, enzymes, or transporters[2]. | ||||||||||||
| In Vivo | Evenamide is active in a wide range of psychiatric animal models in monotherapy and addon to antipsychotics. Evenamide is effective in attenuating the social interaction deficit in Cl 395 (PCP)-impaired rats (MED=1 mg/kg po)[2]. | ||||||||||||
| Name | Evenamide | ||||||||||||
| CAS | 1092977-61-1 | ||||||||||||
| Formula | C16H26N2O2 | ||||||||||||
| Molar Mass | 278.39 | ||||||||||||
| Appearance | Liquid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Valentina Zuliani, et al. Advances in Design and Development of Sodium Channel Blockers. Ion Channels and Their Inhibitors pp 79-115. [2]. Faravelli, et al. P.3.f.022 Evenamide (formerly NW-3509) targets new mechanisms, and represents a new approach to the management of untreated symptoms in schizophrenia. |
Evenamide
CAS: 1092977-61-1 F: C16H26N2O2 W: 278.39
Evenamide (NW-3509) is an orally availablevoltage-gated sodium channel (VGSC) blocker (Ki=0.4 µM) for the research of s
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.